Cortoss shows one-year promise in US vertebral trial
This article was originally published in Clinica
Executive Summary
Preliminary results from Orthovita's first US pilot study of its Cortoss synthetic biomaterial as a treatment for vertebral compression fractures have indicated that the product leads to a rapid, and significant reduction in pain and restoration of function that is maintained 12 months after treatment.